What does the research say about AKR1B3?

AKR1B3

There are 3 papers on AKR1B3 in aging research: none in people yet, 2 in animals, 1 in cells. The newest story, Oct 25, 2026: “Epalrestat reduced bone loss in mouse disease models”.

Gene

3 papers study it1 finding

1 new paper in 30 daysSee all 3 papers on AKR1B3

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

1 lab in 1 country

Funders: National Heart, Lung, and Blood Institute and 1 more

Animals2
Cells1

Associations

Obesity

upin mice1

1 study

AKR1B3 raises the risk of obesity in mice (genetic deletion in high-fat-diet-fed mice).
“Genetic deletion of Akr1b3 or pharmacological blockade of AKRIB3 with zopolrestat reduced high-fat-diet-induced obesity”
Animalsgenetic deletion in high-fat-diet-fed mice
Aldose reductase promotes diet-induced obesity via induction of senescence in subcutaneous adipose tissue
Obesity (Silver Spring, Md.)Jul 28, 2022

Latest

1 paper in 12 months

Pharmacological ResearchOct 25

Epalrestat reduced bone loss in mouse disease models

Early-intervention experiments tested the drug in mice with diabetes or bone loss induced by ovary removal or inflammation.Early-intervention experiments tested the drug in mice with diabetes or bone loss induced by ovary removal or inflammation.

Mouse studyBones and joints